Glaukos (NYSE:GKOS) Price Target Lowered to $104.00 at BTIG Research

Key Points

• BTIG Research has lowered Glaukos' price target from $118.00 to $104.00, while maintaining a "buy" rating on the stock, indicating a potential upside of 25.98%.
• Other institutions have mixed ratings on Glaukos, with Zacks downgrading it to "hold," while Citigroup set a new price target of $110.00 but maintains a "buy" rating.
• Glaukos reported a quarterly earnings surprise with an EPS of ($0.24), surpassing analysts' expectations, and its revenue increased by 29.7% year-over-year.

Glaukos (NYSE:GKOS - Get Free Report) had its price objective reduced by equities researchers at BTIG Research from $118.00 to $104.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a "buy" rating on the medical instruments supplier's stock. BTIG Research's price target would indicate a potential upside of 25.98% from the company's previous close.

GKOS has been the subject of a number of other research reports. Zacks Research downgraded shares of Glaukos from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. Mizuho set a $130.00 price target on shares of Glaukos in a report on Thursday, July 31st. Truist Financial cut their price target on shares of Glaukos from $126.00 to $120.00 and set a "buy" rating for the company in a report on Monday, September 22nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Glaukos in a report on Wednesday, October 8th. Finally, Citigroup dropped their target price on shares of Glaukos from $140.00 to $110.00 and set a "buy" rating for the company in a report on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $116.92.

Glaukos Trading Down 5.1%

GKOS opened at $82.55 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. The company's 50 day simple moving average is $87.95 and its two-hundred day simple moving average is $92.61. Glaukos has a 1-year low of $77.10 and a 1-year high of $163.71. The firm has a market capitalization of $4.73 billion, a price-to-earnings ratio of -50.03 and a beta of 0.76.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. The business had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business's revenue was up 29.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.52) EPS. Glaukos has set its FY 2025 guidance at EPS. Analysts expect that Glaukos will post -1.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Glaukos

Institutional investors have recently modified their holdings of the company. Valeo Financial Advisors LLC lifted its stake in shares of Glaukos by 1.5% during the first quarter. Valeo Financial Advisors LLC now owns 7,817 shares of the medical instruments supplier's stock valued at $769,000 after buying an additional 117 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Glaukos by 16.2% during the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier's stock valued at $99,000 after buying an additional 136 shares during the period. Bessemer Group Inc. lifted its stake in shares of Glaukos by 133.9% during the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock valued at $27,000 after buying an additional 158 shares during the period. First Horizon Advisors Inc. lifted its stake in shares of Glaukos by 72.9% during the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after buying an additional 159 shares during the period. Finally, Park Place Capital Corp lifted its stake in shares of Glaukos by 68.4% during the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier's stock valued at $41,000 after buying an additional 162 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.